Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anixa Biosciences

2.80
+0.04001.45%
Volume:40.19K
Turnover:109.07K
Market Cap:90.15M
PE:-7.11
High:2.83
Open:2.76
Low:2.65
Close:2.76
Loading ...

Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

Simply Wall St.
·
14 Jan

iAccess Alpha's Buyside Best Ideas Virtual Winter Conference December 10-11, 2024

ACCESSWIRE
·
06 Dec 2024

Anixa Biosciences, Inc. (NASDAQ:ANIX) Shares Could Be 20% Below Their Intrinsic Value Estimate

Simply Wall St.
·
04 Dec 2024

Anixa rises as board approves Bitcoin as a treasury reserve asset

seekingalpha
·
23 Nov 2024

BRIEF-Anixa Biosciences Board Of Directors Approves Purchase Of Bitcoin As Treasury Reserve Asset

Reuters
·
22 Nov 2024

Anixa Biosciences board approves purchase of Bitcoin as treasury reserve asset

TIPRANKS
·
22 Nov 2024

Anixa Biosciences Inc: Reaffirmed Its Ongoing Stock Buyback Program

THOMSON REUTERS
·
22 Nov 2024

Anixa Biosciences Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset

THOMSON REUTERS
·
22 Nov 2024

Anixa Biosciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
20 Nov 2024

Anixa Biosciences Price Target Maintained With a $7.00/Share by HC Wainwright & Co.

Dow Jones
·
19 Nov 2024

Anixa Biosciences Gains Buy Rating from Yi Chen Amid Promising Cancer Therapy Advances

TIPRANKS
·
19 Nov 2024

BRIEF-Anixa Biosciences Initiates Dosing In Third Cohort In Its Ovarian Cancer Car-T Clinical Trial

Reuters
·
18 Nov 2024

Anixa Biosciences Initiates Dosing in Third Cohort in Its Ovarian Cancer CAR-T Clinical Trial

THOMSON REUTERS
·
18 Nov 2024

Anixa Biosciences Inc - No Dose Limiting Toxicity Observed in First and Second Cohorts

THOMSON REUTERS
·
18 Nov 2024

Sidoti Events, LLC's Virtual November Micro-Cap Conference

ACCESSWIRE
·
12 Nov 2024

Anixa Biosciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
12 Nov 2024

Anixa Biosciences Reports Promising Phase 1 Vaccine Results

TIPRANKS
·
09 Nov 2024

Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data From Phase 1 Study of Breast Cancer Vaccine at the 39TH Society for Immunotherapy of Cancer (SITC) Annual Meeting

THOMSON REUTERS
·
09 Nov 2024

BRIEF-Anixa Biosciences Announces Timing Of Public Release Of Data From The Phase 1 Study Of Its Breast Cancer Vaccine

Reuters
·
06 Nov 2024

Anixa Biosciences Announces Timing of Public Release of Data From the Phase 1 Study of Its Breast Cancer Vaccine at the 39TH Society for Immunotherapy of Cancer (SITC) Annual Meeting

THOMSON REUTERS
·
06 Nov 2024